BioNTech

BioNTech SE (short for Biopharmaceutical New Technologies) is a Mainz-based German biotechnology firm that develops and manufactures active immunotherapies for patient-specific approaches to illness treatment. It creates pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as personalized cancer immunotherapies, vaccines against infectious diseases, and protein replacement therapies for rare diseases, as well as engineered cell therapy, novel antibodies, and small molecule immunomodulators for cancer treatment.

To deliver individualized mRNA-based cancer immunotherapy to clinical trials and to establish its own manufacturing method, the business has developed an mRNA-based human therapeutic for intravenous injection.

In 2020, BioNTech, in collaboration with Pfizer for testing and logistics, produced the RNA vaccine BNT162b2 for preventing COVID-19 infections, which had a 91% efficacy at the time in preventing proven COVID-19 infections occurring at least 7 days after the second dose of vaccine. The United Kingdom government granted interim HMR authorization for BNT162b2 vaccinations within the United Kingdom on December 2, 2020. It was the first mRNA vaccination to be approved. The vaccine was given emergency permission in the United States, Canada, and Switzerland a few days later.

The European Commission authorized BioNTech/Pfizer's coronavirus vaccine on December 21, 2020, based on the European Medicines Agency's (EMA) favourable recommendation.

Founded: 2008

Headquarters: Mainz, Germany

Website: https://www.biontech.com/de/de/home.html